Search

Your search keyword '"Biological products industry -- Physiological aspects"' showing total 126 results
Start Over Descriptor "Biological products industry -- Physiological aspects"
126 results on '"Biological products industry -- Physiological aspects"'

1. RedHill Biopharma reports positive obesity and diabetes results with opaganib

Subjects
Biological products industry -- Physiological aspects, Pharmaceuticals and cosmetics industries
Abstract

RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced positive results from multiple in vivo studies, undertaken by RedHill's partner, Apogee Biotechnology Corporation, showing the impact of opaganib on weight gain [...]

Published
2024

2. Genentech to Reintroduce Susvimo for People With Wet Age-related Macular Degeneration (AMD)

Subjects
United States. Food and Drug Administration, Roche Holding AG, Biological products industry -- Physiological aspects, Biotechnology industry -- Physiological aspects, Macular degeneration -- Drug therapy, General interest, News, opinion and commentary, Susvimo (Medication)
Abstract

SAN FRANCISCO: GENENTECH has issued the following news release: Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced the reintroduction of Susvimo(r) (ranibizumab injection) 100 mg/mL [...]

Published
2024

3. Genentech to Reintroduce Susvimo for People With Wet Age-related Macular Degeneration (AMD)

Subjects
United States. Food and Drug Administration, Genentech Inc., Roche Holding AG, Biological products industry -- Physiological aspects, Blindness -- Physiological aspects, Biotechnology industry -- Physiological aspects, Macular degeneration -- Physiological aspects, Business, Business, international, Susvimo (Medication), Lucentis (Medication)
Abstract

- The FDA has approved updates to Susvimo, which will be available to U.S. retina specialists and patients with wet AMD in the coming weeks - - Susvimo offers the [...]

Published
2024

4. Connect Biopharma to Participated in the Leerink Partners I&I and Metabolism Therapeutics Forum

Subjects
Biological products industry -- Physiological aspects, Chief financial officers -- Physiological aspects, General interest, News, opinion and commentary
Abstract

SAN DIEGO: Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect or the Company), a U.S.-headquartered, global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through [...]

Published
2024

5. Connect Biopharma to Participate in the Leerink Partners I&I and Metabolism Therapeutics Forum

Subjects
Biological products industry -- Physiological aspects, Chief financial officers -- Physiological aspects, Banking, finance and accounting industries, Business
Abstract

SAN DIEGO, CA and TIACANG, China, July 01, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect or the Company), a U.S.-headquartered, global clinical-stage biopharmaceutical company dedicated to [...]

Published
2024

6. Global Sulfatases Market Forecasts to 2028, with Competitor Analysis for Bayer, BASF, Yara, Compass Minerals, Sumitomo Chemicals, UPL, Israel Chemical Company, Novozymes & Syngenta Crop Protection

Subjects
Biological products industry -- Physiological aspects, Pesticides industry -- Physiological aspects, Herbicides -- Physiological aspects, Chemical industry -- Physiological aspects, Sulfates -- Physiological aspects, General interest, News, opinion and commentary
Abstract

DUBLIN: Research and Markets has issued the following news release: The 'Global Sulfatases Market - Forecasts from 2023 to 2028' report has been added to ResearchAndMarkets.com's offering. The global sulfatases [...]

Published
2024

7. Study Findings from McGill University Broaden Understanding of Lipoproteins (Identification of high-performing antibodies for Apolipoprotein E for use in Western Blot and immunoprecipitation [version 3; peer review: 1 approved, 2 approved with ...)

Subjects
Merck KGaA, Bayer AG, Bristol-Myers Squibb Co., Pfizer Inc., Boehringer Ingelheim GmbH, Biological products industry -- Physiological aspects, Viral antibodies -- Physiological aspects, Apolipoproteins -- Physiological aspects, Blood lipids -- Physiological aspects, Antibodies -- Physiological aspects, Pharmaceutical industry -- Physiological aspects, Biological sciences, Health, McGill University
Abstract

2024 JAN 16 (NewsRx) -- By a News Reporter-Staff News Editor at Life Science Weekly -- Investigators discuss new findings in lipoproteins. According to news originating from Quebec, Canada, by [...]

Published
2024

8. Researchers from Gilead Sciences Inc. Describe Research in Biopharmaceutical Companies (Recent advances in the translation of drug metabolism and pharmacokinetics science for drug discovery and development)

Subjects
Gilead Sciences Inc., Biological products industry -- Physiological aspects, Drug discovery -- Physiological aspects, Physical fitness -- Physiological aspects, Health
Abstract

2022 JUL 2 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators publish new report on biopharmaceutical companies. According to news reporting out [...]

Published
2022

9. Genentech's Vabysmo Boasts Increasingly Favorable Perceptions Among Ophthalmologists for the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema, According to Spherix Global Insights

Subjects
Biological products industry -- Physiological aspects, Dropsy -- Physiological aspects, Macular degeneration -- Physiological aspects, Edema -- Physiological aspects, Ophthalmology -- Physiological aspects, General interest, News, opinion and commentary, Eylea (Medication), Vabysmo (Medication)
Abstract

EXTON: Spherix Global Insights has issued the following news release: Genentech's Vabysmo got an 18-month head start over Regeneron's high dose Eylea (8mg aflibercept), but that lead time may be [...]

Published
2023

10. Genentech's Vabysmo Boasts Increasingly Favorable Perceptions Among Ophthalmologists for the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema, According to Spherix Global Insights

Subjects
Biological products industry -- Physiological aspects, Macular degeneration -- Physiological aspects, Ophthalmology -- Physiological aspects, Drug approval -- Physiological aspects, Business, News, opinion and commentary, Eylea (Medication), Vabysmo (Medication)
Abstract

Despite Vabysmo's positive first impressions, the race is about to heat up with the widely anticipated FDA approval of Regeneron's 8mg aflibercept potentially around the corner. EXTON, Pa., June 7, [...]

Published
2023

11. First biosimilar approved by FDA to treat common eye degeneration in elders

Author

Lasek, Alicia

Subjects
Biogen Inc., Novartis AG, Roche Holding AG, Biological products industry -- Physiological aspects, Generic drugs -- Physiological aspects, Biotechnology industry -- Physiological aspects, Macular degeneration -- Drug therapy, Drug approval -- Physiological aspects, Pharmaceutical industry -- Physiological aspects, Business, Health, Health care industry, Seniors, Lucentis (Medication)
Abstract

The Food and Drug Administration https://www.fda.gov/news-events/press-announcements/fda-approves-first-biosimilar-treat-macular-degeneration-disease-and-other-eye-conditions a less expensive copy of the blockbuster drug Lucentis for treating neovascular (wet) age-related macular degeneration and related eye conditions. Wet macular degeneration causes [...]

Published
2021

12. New Study Findings from Hellenic Pasteur Institute Illuminate Research in Hepatitis C Virus (Differential Expression of the Host Lipid Regulators ANGPTL-3 and ANGPTL-4 in HCV Infection and Treatment)

Subjects
Gilead Sciences Inc., Biological products industry -- Physiological aspects, Antiviral agents -- Physiological aspects, Hepatitis C virus -- Physiological aspects, Infection -- Development and progression, Physical fitness -- Physiological aspects, Health
Abstract

2021 AUG 28 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Current study results on hepatitis C virus have been published. According to [...]

Published
2021

13. French Competition Authority Decision: Decision 20-D-11 of September 09, 2020 relating to practices implemented in the age-related macular degeneration (AMD) treatment sector

Subjects
Genentech Inc., Roche Holding AG, Biological products industry -- Physiological aspects, Biotechnology industry -- Physiological aspects, Macular degeneration -- Drug therapy, News, opinion and commentary, Lucentis (Medication), Avastin (Medication)
Abstract

Paris, France: French Competition Authority has issued the following decision on (September 09, 2020): Presentation of the decision Resume Pursuant to the decision below, several companies of the Novartis group [...]

Published
2023

14. Lineage Launches Phase 2a Study by Genentech of RG6501 in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Subjects
Cell Therapeutics Inc., Roche Holding AG, Biological products industry -- Physiological aspects, Biotechnology industry -- Physiological aspects, Macular degeneration -- Care and treatment, Clinical trials -- Physiological aspects, Pharmaceutical industry -- Physiological aspects, General interest, News, opinion and commentary
Abstract

CARLSBAD, Calif.: Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced that its partner Genentech, a member of the Roche Group, has [...]

Published
2022

15. OrsoBio Launches to Develop Novel Therapies for Patients with Severe Metabolic Disorders

Subjects
Gilead Sciences Inc., Biological products industry -- Physiological aspects, Liver -- Physiological aspects, Venture capital companies -- Physiological aspects, Type 2 diabetes -- Physiological aspects, Business, Business, international, Yale University
Abstract

-- Company advances two clinical and two preclinical programs targeting fundamental aspects of energy metabolism -- PALO ALTO, Calif. -- OrsoBio, Inc., a clinical-stage biopharmaceutical company developing treatments for severe [...]

Published
2022

16. Glabridin induces apoptosis and autophagy through JNK1/2 pathway in human hepatoma cells

Author

Hsieh, Ming-Ju, Chen, Mu-Kuan, Chen, Chih-Jung, Hsieh, Ming-Chang, Lo, Yu-Sheng, Chuang, Yi-Ching, Chiou, Hui-Ling, and Yang, Shun-Fa

Subjects
Sigma Chemical Co., Biological products industry -- Physiological aspects, B cells -- Physiological aspects, Liver cancer -- Physiological aspects, Apoptosis -- Physiological aspects, Biological sciences, Health, Science and technology
Abstract

ABSTRACT Background: Extensive research results support the use of herbal medicine or natural food to augment therapy for various cancers. Studies have associated glabridin with numerous biological activities, such as [...]

Published
2016
Full Text
View/download PDF

17. Data on Age-Related Macular Degeneration Reported by Researchers at Genentech Inc. (Integration of eQTL and a Single-Cell Atlas in the Human Eye Identifies Causal Genes for Age-Related Macular Degeneration)

Subjects
Macular degeneration -- Physiological aspects, Physical fitness -- Physiological aspects, Genes -- Physiological aspects, Biochemistry -- Physiological aspects, Medical research -- Physiological aspects, Eye diseases -- Physiological aspects, Biological products industry -- Physiological aspects, Anopheles, Epithelium, Finance, Biotechnology industries, Diseases, Obesity, Editors, Health
Abstract

2020 FEB 15 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- A new study on Eye Diseases and Conditions - Age-Related Macular Degeneration [...]

Published
2020

18. Studies from Genentech Inc. in the Area of Breast Cancer Reported (Predictive and Pharmacodynamic Biomarkers of Response to the Phosphatidylinositol 3-Kinase Inhibitor Taselisib in Breast Cancer Preclinical Models)

Subjects
Women's health -- Physiological aspects, Phospholipids -- Physiological aspects, Cancer research -- Physiological aspects, Fulvestrant -- Research -- Physiological aspects, Breast cancer -- Research -- Physiological aspects, Biological products industry -- Physiological aspects, Genes, Anopheles, Biological markers, Editors, Biotechnology industries, Health, Women's issues/gender studies
Abstract

2020 JAN 30 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Investigators publish new report on Oncology - Breast Cancer. According to news reporting originating [...]

Published
2020

19. New Two-Year Data Confirm Genentech's Vabysmo Improved Vision With Fewer Treatments for People With Wet Age-Related Macular Degeneration

Subjects
Roche Holding AG, Biological products industry -- Physiological aspects, Biotechnology industry -- Physiological aspects, Macular degeneration -- Care and treatment, Business, international, Vabysmo (Medication)
Abstract

SOUTH SAN FRANCISCO, Calif.: Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced new two-year data from the TENAYA and LUCERNE studies that reinforce the [...]

Published
2022

20. New Two-Year Data Confirm Genentech's Vabysmo Improves Vision With Fewer Treatments for People With Wet Age-Related Macular Degeneration

Subjects
Genentech Inc., Roche Holding AG, Biological products industry -- Physiological aspects, Biotechnology industry -- Physiological aspects, Macular degeneration -- Care and treatment, Business, Business, international, Vabysmo (Medication)
Abstract

In the TENAYA and LUCERNE studies, more than 60% of Vabysmo patients could be treated every four months at two years. This represents an increase from 45% at year one [...]

Published
2022

21. Changes Afoot in US Age-Related Macular Degeneration Market as Prescribers Brace for the Launch of Biogen and Samsung Bioepis' Byooviz, According to Spherix Global Insights

Subjects
Biological products industry -- Physiological aspects, Macular degeneration -- Physiological aspects, Drug approval -- Physiological aspects, General interest, News, opinion and commentary, Lucentis (Medication), Avastin (Medication), Byooviz (Medication)
Abstract

EXTON: Spherix Global Insights has issued the following news release: After several years of lackluster reception towards off-label biosimilar, Genentech's Avastin (bevacizumab), ophthalmologists have finally seen the greenlight of a [...]

Published
2022

22. Lineage Launches Phase 2a Study by Genentech of RG6501 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration

Subjects
Cell Therapeutics Inc., Roche Holding AG, Biological products industry -- Physiological aspects, Macular degeneration -- Care and treatment, Clinical trials -- Physiological aspects, Chemistry
Abstract

M2 PHARMA-November 28, 2022-Lineage Launches Phase 2a Study by Genentech of RG6501 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration (C)2022 M2 COMMUNICATIONS - US-based biotechnology company Lineage [...]

Published
2022

23. New Findings from Genentech Inc. Describe Advances in Apoptosis (Cleavage of RIPK1 by caspase-8 is crucial for limiting apoptosis and necroptosis)

Subjects
Apoptosis -- Physiological aspects, Physical fitness -- Physiological aspects, Cysteine -- Physiological aspects, Proteases -- Physiological aspects, Gastrointestinal diseases -- Research -- Physiological aspects, Biological products industry -- Physiological aspects, Biochemistry, Aspartate, Cystine, Biotechnology industries, Cell death, Obesity, Editors, Immunodeficiency, Health
Abstract

2019 NOV 16 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Current study results on Cellular Physiology - Apoptosis have been published. According [...]

Published
2019

24. Reports from Genentech Inc. Highlight Recent Findings in Apoptosis (Cleavage of RIPK1 by caspase-8 is crucial for limiting apoptosis and necroptosis)

Subjects
Genentech Inc., Apoptosis -- Physiological aspects, Physical fitness -- Physiological aspects, Biotechnology industries -- Physiological aspects, Cysteine -- Physiological aspects, Proteases -- Physiological aspects, Gastrointestinal diseases -- Research -- Physiological aspects, Biological products industry -- Physiological aspects, Biochemistry, Aspartate, Cystine, Cell death, Obesity, Editors, Immunodeficiency, Health
Abstract

2019 SEP 28 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Current study results on Cellular Physiology - Apoptosis have been published. According [...]

Published
2019

25. Data on Cancer Reported by Researchers at Genentech Inc. (Engineering Interferons and Interleukins for Cancer Immunotherapy)

Subjects
Oncology, Experimental -- Physiological aspects, Biological products industry -- Physiological aspects, Interferon -- Physiological aspects, Immunotherapy -- Physiological aspects, Cancer -- Development and progression -- Drug therapy -- Research, Interleukins -- Physiological aspects, Health
Abstract

2022 AUG 17 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Fresh data on Cancer are presented in a new report. According to news reporting out [...]

Published
2022

26. Reports on Age-Related Macular Degeneration from Genentech Inc. Provide New Insights (Development of the Port Delivery System With Ranibizumab for Neovascular Age-related Macular Degeneration)

Subjects
Genentech Inc., Biological products industry -- Physiological aspects, Eye diseases -- Care and treatment, Biotechnology industry -- Physiological aspects, Vascular endothelial growth factor -- Physiological aspects, Macular degeneration -- Care and treatment, Health
Abstract

2022 JUN 24 (NewsRx) -- By a News Reporter-Staff News Editor at Angiogenesis Weekly -- Investigators publish new report on Eye Diseases and Conditions - Age-Related Macular Degeneration. According to [...]

Published
2022

27. NewsFlash:Codexis Presents Pre-Clinical Data Highlighting its Programs in Homocystinuria and Maple Syrup Urine Disease at ICIEM 2021

Subjects
Codexis Inc., Biological products industry -- Physiological aspects, General interest, News, opinion and commentary
Abstract

Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that two of the Company's wholly owned biotherapeutic programs, CDX-6512 for the treatment [...]

Published
2021

28. Codexis Schedules Presentation at ICIEM 2021

Subjects
Codexis Inc., Biological products industry -- Physiological aspects, Enzymes -- Physiological aspects, General interest, News, opinion and commentary
Abstract

REDWOOD CITY, Calif.: Codexis, Inc., a leading enzyme engineering company enabling the promise of synthetic biology, announced that two of the Company's wholly-owned biotherapeutic programs, CDX-6512 for the treatment of [...]

Published
2021

29. Codexis Presents Pre-Clinical Data Highlighting its Programs in Homocystinuria and Maple Syrup Urine Disease at ICIEM 2021

Subjects
Codexis Inc., Biological products industry -- Physiological aspects, Amino acids -- Physiological aspects, Banking, finance and accounting industries, Business
Abstract

REDWOOD CITY, Calif., Nov 22, 2021 (GLOBE NEWSWIRE via COMTEX) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that two [...]

Published
2021

30. FDA green lights Genentech's eye implant for macular degeneration. Will it be a tough sell?

Author

Dunleavy, Kevin

Subjects
Biological products industry -- Physiological aspects, Prosthesis -- Physiological aspects, Implants, Artificial -- Physiological aspects, Macular degeneration -- Physiological aspects, Pharmaceuticals and cosmetics industries, Lucentis (Medication)
Abstract

Byline: Kevin Dunleavy Two treatments per year as opposed to 12, what's not to like? In two words--surgical implants. That's the stigma Genentech will potentially face as it attempts to [...]

Published
2021

31. FDA Approves Samsung Bioepis and Biogen's BYOOVIZ to Treat Neovascular Age-Related Macular Degeneration

Subjects
United States. Food and Drug Administration, Biogen Inc., Biological products industry -- Physiological aspects, Executives -- Physiological aspects, Macular degeneration -- Drug therapy, Drug approval -- Physiological aspects, General interest, News, opinion and commentary, Lucentis (Medication)
Abstract

INCHEON, Korea and CAMBRIDGE, Mass.: Samsung Bioepis Co.,Ltd. and Biogen Inc. announced that the U.S. FDA has approved BYOOVIZ (ranibizumab-nuna), a biosimilar referencing LUCENTIS(r) (ranibizumab) for the treatment of neovascular [...]

Published
2021

32. FDA Accepts Application for Genentech's Faricimab for the Treatment of Wet Age-Related Macular Degeneration (AMD) and Diabetic Macular Edema (DME)

Subjects
United States. Food and Drug Administration, Biological products industry -- Physiological aspects, Diabetic retinopathy -- Care and treatment, Dropsy -- Care and treatment, Macular degeneration -- Care and treatment, Edema -- Care and treatment, General interest, News, opinion and commentary
Abstract

SOUTH SAN FRANCISCO: GENENTECH has issued the following news release: Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug [...]

Published
2021

33. FDA Accepts Application for Genentech's Faricimab for the Treatment of Wet Age-Related Macular Degeneration (AMD) and Diabetic Macular Edema (DME)

Subjects
Genentech Inc., Biological products industry -- Physiological aspects, Medical research -- Physiological aspects, Medicine, Experimental -- Physiological aspects, Biotechnology industry -- Physiological aspects, Macular degeneration -- Care and treatment, Business, Business, international
Abstract

- Across four Phase III studies, approximately half of patients receiving faricimab could extend treatment time to every four months - the first time this level of durability has been [...]

Published
2021

35. Phase III Data Show Port Delivery System With Ranibizumab Enabled Over 98% of Patients to Go Six Months Between Treatments for Neovascular Age-Related Macular Degeneration

Subjects
United States. Food and Drug Administration, Genentech Inc., Roche Holding AG, Macular degeneration -- Care and treatment, Ranibizumab -- Physiological aspects, Biotechnology industries -- Physiological aspects, Biological products industry -- Physiological aspects, Business, Business, international, Lucentis (Medication)
Abstract

* In the Archway study, Port Delivery System with ranibizumab (PDS) demonstrated non-inferior and equivalent visual acuity outcomes compared with monthly ranibizumab eye injections, and a favorable benefit-risk profile * [...]

Published
2020

36. Port Delivery System With Ranibizumab Shows Positive Phase III Results in Neovascular Age-Related Macular Degeneration

Subjects
United States. Food and Drug Administration, Genentech Inc., Roche Holding AG, Macular degeneration -- Physiological aspects, Ranibizumab -- Physiological aspects, Biotechnology industries -- Physiological aspects, Biological products industry -- Physiological aspects, Health, Business, Business, international, Lucentis (Medication)
Abstract

* Port Delivery System with ranibizumab (PDS) is a permanent refillable eye implant that continuously delivers ranibizumab over a period of months, potentially reducing the treatment burden associated with frequent [...]

Published
2020

37. New Drug Metabolism and Disposition Data Have Been Reported by Researchers at Genentech (CYP1A1-Mediated Intramolecular Rearrangement of Aminoazepane in GDC-0339)

Subjects
Physical fitness -- Physiological aspects, Cytochrome P-450 -- Physiological aspects, Metabolites -- Physiological aspects, Multiple myeloma -- Drug therapy -- Physiological aspects, Biological products industry -- Physiological aspects, Health
Abstract

2017 OCT 21 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Current study results on Drugs and Therapies - Drug Metabolism and Disposition [...]

Published
2017

38. Catalyst Biosciences Announces Global License and Collaboration Agreement to Develop Pegylated CB 2782 for the Treatment of Dry Age-Related Macular Degeneration

Subjects
Biogen Inc., Macular degeneration -- Physiological aspects, Biological products industry -- Physiological aspects, Proteases, Production management, General interest, News, opinion and commentary
Abstract

San Francisco:Catalyst Biosciences, Inc. has issued the following press release: Catalyst Biosciences, Inc. (Nasdaq: CBIO), today announced it has entered into a global license and collaboration agreement with Biogen Inc. [...]

Published
2019

39. Catalyst Biosciences Announces Global License and Collaboration Agreement to Develop Pegylated CB 2782 for the Treatment of Dry Age-Related Macular Degeneration

Subjects
Biogen Inc., Macular degeneration -- Physiological aspects, Proteases -- Physiological aspects, Biological products industry -- Physiological aspects, Production management, Business, international, Law
Abstract

(GlobeNewswire) - Catalyst Biosciences, Inc. (Nasdaq: CBIO), today announced it has entered into a global license and collaboration agreement with Biogen Inc. (Nasdaq: BIIB) for the development and commercialization of [...]

Published
2019

40. Catalyst Biosciences Announces Global License and Collaboration Agreement to Develop Pegylated CB 2782 for the Treatment of Dry Age-Related Macular Degeneration

Subjects
Biogen Inc., Macular degeneration -- Physiological aspects, Proteases -- Physiological aspects, Biological products industry -- Physiological aspects, Production management, Banking, finance and accounting industries, Business
Abstract

SOUTH SAN FRANCISCO, Calif., Dec 19, 2019 (GLOBE NEWSWIRE via COMTEX) -- Catalyst Biosciences, Inc. (Nasdaq: CBIO), today announced it has entered into a global license and collaboration agreement with [...]

Published
2019

41. Studies from Genentech Inc. in the Area of Membrane Transport Proteins Described (A Non-covalent Ligand Reveals Biased Agonism of the Trpa1 Ion Channel)

Subjects
United States. National Institutes of Health, Genentech Inc., Biological products industry -- Physiological aspects, Biotechnology industry -- Physiological aspects, Carrier proteins -- Physiological aspects, Biotechnology industry, Pharmaceuticals and cosmetics industries
Abstract

2021 APR 7 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Week -- Investigators publish new report on Carrier Proteins - Membrane Transport Proteins. According to news reporting [...]

Published
2021

42. Investigators at Genentech, Inc. Zero in on Drug Metabolism [Non-Clinical Disposition and Metabolism of DM1, a Component of Trastuzumab Emtansine (T-DM1), in Sprague Dawley Rats]

Subjects
Genentech Inc., Biotechnology industries -- Physiological aspects, Trastuzumab -- Physiological aspects, Biological products industry -- Physiological aspects, Health
Abstract

2016 MAR 12 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Research findings on Drugs and Therapies are discussed in a new report. [...]

Published
2016

43. Investigators from Genentech Inc. Have Reported New Data on Physiology (Intestinal Stem Cell Aging: Origins and Interventions)

Subjects
Stem cells -- Physiological aspects, Stem cell research -- Physiological aspects, Biological products industry -- Physiological aspects, Insects, Epithelium, Biotechnology, Editors, Biotechnology industries, Social science research, Biotechnology industry, Pharmaceuticals and cosmetics industries
Abstract

2020 MAR 11 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Week -- Current study results on Life Science Research - Physiology have been published. According to news [...]

Published
2020

44. Investigators at Genentech Inc. Target Molecular Biology (Proteasome Inhibitors: Harnessing Proteostasis to Combat Disease)

Subjects
Molecular biology -- Physiological aspects, Cellular proteins -- Physiological aspects, Biological products industry -- Physiological aspects, Proteolysis -- Physiological aspects, Proteins, Editors, Biotechnology industries, Diseases, Health
Abstract

2020 FEB 24 (NewsRx) -- By a News Reporter-Staff News Editor at Hematology Week -- Investigators discuss new findings in Biology - Molecular Biology. According to news reporting from South [...]

Published
2020

45. Findings on Heart and Circulatory Physiology Reported by Investigators at Oregon Health & Science University (OHSU) (Ranolazine May Exert Its Beneficial Effects By Increasing Myocardial Adenosine Levels)

Subjects
Gilead Sciences Inc., Ranolazine -- Research -- Physiological aspects, Heart diseases -- Research -- Physiological aspects, Adenosine -- Research -- Physiological aspects, Biological products industry -- Physiological aspects, Stenosis, Myocardial ischemia, Cardiovascular diseases, Finance, Ischemia, Editors, Diseases, Health, Oregon Health & Science University
Abstract

2020 FEB 14 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Current study results on Health and Medicine - Heart and Circulatory Physiology have [...]

Published
2020

46. Researchers from Genentech Research and Early Development Provide Details of New Studies and Findings in the Area of Age-Related Macular Degeneration (Deep Sequencing-guided Design of a High Affinity Dual Specificity Antibody to Target Two ...)

Subjects
Macular degeneration -- Research -- Physiological aspects, Antibodies -- Physiological aspects, Eye diseases -- Research -- Physiological aspects, Biological products industry -- Physiological aspects, Health
Abstract

2015 OCT 10 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- A new study on Eye Diseases and Conditions is now available. According [...]

Published
2015

47. New Stairway Study Data Shows Potential for Extended Durability with Faricimab in Wet Age-Related Macular Degeneration (AMD)

Subjects
United States. Food and Drug Administration, Genentech Inc., Roche Holding AG, Macular degeneration -- Research -- Care and treatment -- Physiological aspects, Biotechnology industries -- Physiological aspects, Biological products industry -- Physiological aspects, Business, Business, international, American Academy of Ophthalmology, Lucentis (Medication)
Abstract

* Faricimab - the first bispecific antibody designed for the eye - dosed every four months demonstrated sustained vision outcomes compared to monthly ranibizumab for people with wet AMD (1 [...]

Published
2018

48. Genentech Unveils Positive Phase II Results for the First-Ever Eye Implant to Achieve Sustained Delivery of a Biologic Medicine to Treat People With Wet Age-Related Macular Degeneration (AMD)

Subjects
Macular degeneration -- Drug therapy -- Physiological aspects, Biological products industry -- Physiological aspects, General interest, News, opinion and commentary
Abstract

SOUTH SAN FRANCISCO: Genentech has issued the following press release: -Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced positive, top line results from the [...]

Published
2018

49. Genentech Unveils Positive Phase II Results for the First-Ever Eye Implant to Achieve Sustained Delivery of a Biologic Medicine to Treat People With Wet Age-Related Macular Degeneration (AMD)

Subjects
United States. Food and Drug Administration, Genentech Inc., Roche Holding AG, Macular degeneration -- Drug therapy -- Physiological aspects, Biotechnology industries -- Physiological aspects, Biological products industry -- Physiological aspects, Business, Business, international, Lucentis (Medication)
Abstract

* Genentech's investigational Port Delivery System with ranibizumab (PDS) is a small, refillable device, slightly longer than a grain of rice, surgically implanted in the eye and uniquely designed to [...]

Published
2018

50. Landos Biopharma Announces Publication of Mechanistic and Human Translational Results for BT-11 in Models of IBD

Subjects
Gastrointestinal diseases -- Physiological aspects, Biological products industry -- Physiological aspects, Business, Business, international
Abstract

BLACKSBURG, Va. -- Landos Biopharma, Inc., an emerging biopharmaceutical company focused on developing improved treatments for autoimmune diseases, announced the publication of findings on the mechanisms of action for its [...]

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results